Detection of Anaplastic Lymphoma Kinase-Rearranged Mesothelioma Cells in Ascites by Companion Diagnostics

2019 ◽  
Vol 64 (4) ◽  
pp. 378-385
Author(s):  
Maho Konishi ◽  
Takahiro Kanyama ◽  
Kenichiro Maeno ◽  
Chiho Miyagawa ◽  
Sachiko Minamiguchi ◽  
...  

Background: A case of peritoneal mesothelioma with an anaplastic lymphoma kinase (ALK) translocation was identified, and we conducted further studies to obtain diagnostic and therapeutic insights. We believe that this is the first report describing the cytology of this new tumor type. Case: A teenage woman was referred for severe pleural effusion. Enhanced computed tomography indicated an abdominal mass with ascites. Laparoscopy revealed tumor dissemination from the pelvis to the upper abdomen. Because a high-grade serous carcinoma was suspected, ascitic cytology and biopsy were performed. Cytologically, the tumor displayed characteristics of both adenocarcinoma and reactive or neoplastic mesothelial cells. After extensive pathological evaluation, the tumor was diagnosed as malignant peritoneal mesothelioma. To verify the diagnosis and aid in developing a therapeutic strategy, several companion diagnostics were tried. Surprisingly, the tumor was ALK-positive, and ALK recombination was confirmed by an ALK break-apart test. Retrospectively, cells and tissue specimens were stained with ALK intercalated antibody-enhanced polymer. Tumor cells were clearly distinguished from the nonneoplastic background. Recombination in ALK was reconfirmed by the National Cancer Center Japan, and the patient was enrolled in a clinical trial for alectinib. Conclusion: Companion diagnostics-based cytology may provide a useful means of monitoring and evaluating a molecular-targeted therapy.

2021 ◽  
Vol 91 (3) ◽  
pp. 475-476
Author(s):  
Shinichiro Sakata ◽  
Helen Rees ◽  
Simon Parke ◽  
Norman J. Carr ◽  
Danko Kostadinov ◽  
...  

2015 ◽  
Vol 68 (4) ◽  
pp. 603-607 ◽  
Author(s):  
Kongsak Loharamtaweethong ◽  
Napaporn Puripat ◽  
Nadda Aoonjai ◽  
Apisada Sutepvarnon ◽  
Chanyoot Bandidwattanawong

Blood ◽  
2010 ◽  
Vol 115 (16) ◽  
pp. 3314-3319 ◽  
Author(s):  
Kamel Ait-Tahar ◽  
Christine Damm-Welk ◽  
Birgit Burkhardt ◽  
Martin Zimmermann ◽  
Wolfram Klapper ◽  
...  

Abstract Anaplastic lymphoma kinase (ALK)–positive anaplastic large cell lymphoma (ALCL) constitutes an ideal model disease to study tumor-specific immune responses. All the tumor cells express oncogenic ALK resulting from a chromosomal translocation involved in lymphomagenesis. Although antibodies and T-cell responses to ALK have previously been detected in ALK-positive ALCL patients, their prognostic significance is unknown. We investigated a large cohort of uniformly treated ALK-positive pediatric ALCL patients to ascertain whether the titers of preexisting ALK autoantibodies correlated with clinical and histologic characteristics, tumor dissemination, and patient outcome. ALK autoantibodies were analyzed in pretherapeutic serum samples from 95 patients enrolled into 2 therapy studies between 1996 and 2007. ALK autoantibodies were detected in 87/95 patients. The titers inversely correlated with stage and amount of circulating tumor cells. High antibody titers correlated with significantly lower cumulative incidence of relapses (CI-R): titers ≥ 1/60 750, n = 29, CI-R 11% ± 6%; titers 1/2025-< 1/60 750, n = 39, CI-R 31% ± 8%; and titers 0-≤ 1/750, n = 27, CI-R of 63% ± 10% (P < .001). Our results provide the first clinical evidence that a robust preexisting immune response to an oncoantigen resulting from an oncogenic chromosomal translocation inhibits lymphoma dissemination and decreases the risk of relapse.


2012 ◽  
Vol 17 (2) ◽  
pp. 123-143 ◽  
Author(s):  
Christina Schonherr ◽  
Bengt Hallberg ◽  
Ruth Palmer

Sign in / Sign up

Export Citation Format

Share Document